cirm.ca.gov2h
CIRM marks 20 years of advancing regenerative medicine in California
South San Francisco, CA, Nov. 14, 2024 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutes dedicated to regenerative medicine, marked a historic ...
cirm.ca.gov7d
CompMoby: comparative MobyDick for detection of cis-regulatory motifs.
BACKGROUND: The regulation of gene expression is complex and occurs at many levels, including transcriptional and post-transcriptional, in metazoans. Transcriptional regulation is mainly determined by ...
cirm.ca.gov20d
7th Annual Alpha Clinic Network Symposium
Sponsored by the California Institute for Regenerative Medicine (CIRM) and hosted by Cedars-Sinai, the 7th Annual Alpha Clinics Network Symposium brings together a wide array of stakeholders, ...
cirm.ca.gov19d
Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and ...
cirm.ca.gov24d
CIRM Executive Team
Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.
cirm.ca.gov22d
Where CIRM Funding Goes
CIRM has one singular mission: Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. A dedication to ...
cirm.ca.gov25d
Year 3
We continue to focus on understanding the role of microRNAs in the development of hematopoietic stem cells from human embryonic stem cells. Progress is slow, but present. We now understand that cells ...
cirm.ca.gov18d
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
Cell-based immunotherapy has become the new-generation cancer medicine, and "off-the-shelf" cell products that can be manufactured at large scale and distributed readily to treat patients are ...
cirm.ca.gov20d
Deborah Deas, MD, MPH
Deborah Deas, MD, MPH es vicerrectora de Ciencias de la Salud, decana Mark y Pam Rubin de la Facultad de Medicina y profesora distinguida de psiquiatría de la Universidad de California, Riverside (UCR ...
cirm.ca.gov28d
CIRM Team Leads
Geoffrey Lomax, DrPH, joined the California Institute for Regenerative Medicine in 2005. He is the Associate Director for CIRM’s Patient Access Team. The team manages CIRM’s Clinical Infrastructure ...
cirm.ca.gov20d
Arterialized collateral capillaries progress from nonreactive to capable of increasing perfusion in an ischemic arteriolar tree.
Natural bypass arteries, i.e. collaterals, can improve the prognosis in patients with occlusive artery disease. Unfortunately, some patients never develop identifiable collaterals. However in animal ...